Company Profile

Year Established : 2022
Main Competitive Advantages : Experienced R&D Staff,Delivery Term,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Quality Service
Other Competitive Advantages : The company originated from the State Key Laboratory of Bioreactor of East China University of Science and Technology and the Collaborative Innovation Center jointly built by the Ministry of Shanghai Bio-manufacturing Industry. The company's R&D center is located in Shanghai Caohejing Development Zone, with a group of experienced management team and efficient R&D team, including many outstanding experts in the fields of new enzyme mining, molecular modification, drug synthesis, process development, microbial fermentation and metabolic engineering. It has a high reputation and strong competitiveness in many important fields such as synthetic biology, enzyme engineering, fermentation engineering, pharmaceutical chemistry, and product engineering.
  • Contact Person :
  • Fax:

Bioforany was established in 2014 as one of the main pioneers of China's biocatalytic industry. It has a comprehensive synthetic biology technology platform, advanced enzyme engineering platform, and enzyme based green process development technology, and has established long-term and close strategic cooperation relationships with multiple well-known biochemical enterprises.


Professor Xu Jianhe, the founder , is a leading scholar in the field of "enzyme engineering" in China. He has rich professional knowledge and practical experience in engineering, and has reached technical cooperation with nearly 20 downstream companies relying on a unique enzyme technology platform. He has completed multiple product technology research and development from scratch to large-scale production.

 

At present, Bioforany has built an over 3000 types of industrial leading enzyme library with complete intellectual property right, broad-spectrum universality, and high representativeness "1 leading enzyme library"﹢"3 technology platforms"﹢ "7 commercial products". By the end of 2023, three products can be commercialized and mass-produced.

PharmaSources Customer Service